Lack of effective disease models is one of the important reasons for the low success rate of CNS drug development. TriApex provides non-human primate (NHP) models for a variety of central nervous system diseases. The core team is staffed by scientists in the fields of neurology, clinical medicine and neuropharmacology, of which masters and doctors accounting for 80%, and committed to the establishment of CNS disease models and pharmacological/pharmacodynamic research.
Project ExperienceDrug | Indication | Studies | Number of Animals Used |
AAV | Spinal cord injury | NA | 12 |
Small molecule | Alzheimer's disease | NA | 48 |
Small molecule | Cerebral stroke | NA | 40 |
NA | Cerebral stroke | IND | 40 |
NA | Parkinson's disease | NA | 40 |
Official WeChat account
苏公网安备32011202001081 
Regulatory Policies
Project Management
Global
